Behtash G Nezami

Behtash G Nezami, MD serves as Assistant Professor in the Department of Pathology at Northwestern University Feinberg School of Medicine, specializing in Molecular Pathology and Genitourinary Pathology. His clinical practice integrates advanced molecular diagnostics with subspecialized urological pathology expertise.

Education:

• MD: Tehran University of Medical Sciences
• Residency: Case Western Reserve University (Anatomic and Clinical Pathology, 2020)
• Fellowship: MD Anderson Cancer Center (Molecular Genetic Pathology, 2021)
• Fellowship: Memorial Sloan Kettering Cancer Center (Genitourinary Pathology, 2022)

Dr. Nezami's research pioneers the convergence of digital pathology and artificial intelligence in genitourinary oncology, with emphasis on computational tumor analysis and molecular characterization. His work bridges molecular diagnostics with clinical pathology to develop prognostic tools for bladder and kidney cancers, while expanding digital pathology applications in gender-affirmation surgery and metastatic cancer classification. This dual focus on computational innovation and subspecialized diagnostics establishes new paradigms for precision pathology.

His 2025 publications reveal a decisive shift toward AI-integrated diagnostic workflows, with computational morphology predicting cancer recurrence, digital pathology enhancing surgical specimen analysis, and multimodal molecular testing resolving diagnostic uncertainties in metastatic disease. These works collectively advance pathology toward quantitative, data-driven decision support systems while addressing critical gaps in renal tumor classification and transgender healthcare.

Scientific Awards:

• 2025 Best Author Award (Pathology outlines)

Dr. Nezami maintains active leadership across major pathology organizations including AMP, CAP, USCAP, and GUPS, driving advancements in molecular diagnostics standards and genitourinary pathology education. His multilingual capabilities (English and Farsi) enhance cross-cultural patient care and international collaboration. Current research focuses on developing AI-powered diagnostic tools for cancer prognostication while expanding molecular testing frameworks for challenging clinical cases.

His laboratory team specializes in digital pathology algorithm development and molecular tumor profiling, with ongoing projects optimizing computational assessment of bladder cancer recurrence and refining classification systems for renal neoplasms through integrated genomic-pathologic analysis.